 Thank you very much. This is a moment where I can be truly grateful for a lot of things. One, Jeff, those are, I think, really amazingly gracious remarks. You are a dear friend and colleague. It's not a past tense. It will continue to be that way. It is true that I have enjoyed every moment with you and the school. People ask me, why are you leaving after three years? And I guess my response now is, it was three years. And it's time to move on to other things. But certainly, it was not a lack of very important things that we think we did. And I think we're going to do other things in addition. So this is kind of an embarrassing thing to be in front of everybody and receiving this very nice award. It's embarrassing because I'm not exactly sure I deserve it. And secondly, I'm keeping you on a very long day and keeping you from cocktails. I know I'm doing that. So I say I'm grateful to Jeff's comments. But I also am grateful to Karun Rishi. Karun has been the mastermind, the one who's been really developing all that you see at the US India Chamber of Commerce meeting the Biopharmist Summit. I think some of us have just been lucky, blessed. Martin, myself, many others here to be invited from time to time to help out. And so thank you for inviting me to do that, Karun, for having the faith and trust that we actually will do something interesting and useful. I hope it's been useful. But really, I congratulate you, honestly, for the great effort that you do. Because I think this summit is a terrific meeting. I think it's an essential meeting to have a forum that allows all of us from different sectors, from government, particularly the Indian government, from industry, from academia. There are occasionally patient groups that are involved to really think deeply about how we can really use this ecosystem to do a lot better, a lot better for our patients, a lot better for public health. How do we really, in many ways, create new drugs, devices, diagnostics for our patients in a faster, more efficient, effective way? If we can do that, we will have done something quite important. You know, I go to a new job. And when I tell people I'm going to farm up, those who are not in the business say, why are you doing that? It's a horrible organization. All it does is to lobby for increased prices, increase exclusivity. Well, those in the business really argue that those are important in order to keep the business going. But ultimately, the public is not happy about what we do in one sense. And that is that we really don't allow much access to medicines as we really need to do. And so as FALMA is a group that deals with lobbying and advocacy, there needs to be a voice of science in that conversation. And I quickly come back to this meeting, which really articulates and continues that conversation of what the intersect of science in academia, in industry, in government, in investors, in patient groups do in order to allow us to do all the things that we have to do. Let me step back for one second. I promise this will be not very long. But the deal is that with Jeff at Harvard Medical School, our key goal is to alleviate human suffering caused by disease. Well, that's certainly not unique to Harvard Medical School. It's something that we all embrace, that we're all in this to alleviate human suffering caused by disease. This is a global challenge. We've heard this time and time again at this meeting, that there are no boundaries relative to diseases and the suffering that it causes. So what we need to do is to really understand more and more the role of this ecosystem as complex as it is. Today, we had a chance to talk about the cultural gulfs that prevent a lot of activity. I think even with the last panel, we talked about how do we understand each other to work better together. And it's about education. It's about communications. And we still have a lot to do, but it's a very important thing to do in order to be able to get where we want to go. One of the things that I remember, Martin, you might have said this to Karun as well. He said, look, there are a lot of times when we get together and we talk. Talk is cheap. We could talk forever. But what is it that we could do as a group that was truly actionable, small? Let's pick out small things. And I think Karun, with the group, has been able to make some headway relative to issues of education, et cetera. But I think we need to do much more. And I really do think that this organization, the summit, will continue to do more of this. And well, we heard today from Ajay that, of course, when you work with India and maybe other countries, it's a slow process. To expect great changes fast, I think that's really not very possible. So I'm going to conclude by saying that I am de-grateful. I'm grateful for this honor. I honestly do believe I don't deserve this because I have actually enjoyed it all the moments I've been here to help with the effort. A rule of thumb in my life has always been, am I having fun? And I would say every moment I've spent with Karun and the group really involved fun, although it meant also answering emails and phone calls very often. Right, Martin? That was a constant. So I want to thank you for your attention. And again, I'm not going to hold you much longer. And I am deeply appreciative of the honor. And I hope that this doesn't mean that I'm now officially retired from this summit. I think Karun's not going to let that happen, right, Karun? And so without further ado, have a good cocktail reception. So thank you very much. Thank you.